LAVA Therapeutics (LVTX) Company Report

LAVA Therapeutics N.V. announced that 22,877,463 common shares, representing approximately 87% of its outstanding common shares, were validly tendered and not withdrawn in XOMA Royalty Corporation's tender offer, satisfying the minimum tender condition and other conditions.
All validly tendered shares are expected to be accepted for payment on or about November 13, 2025.
A subsequent offering period has commenced and will expire one minute after 11:59 p.m. Eastern Time on November 20, 2025.
LAVA's common shares are expected to be suspended from trading on the Nasdaq Global Select Market prior to the opening of the market on or about November 21, 2025, and the company has submitted written notice of its intention to voluntarily delist.

Nov 13, 2025, 12:30 PM

LAVA Therapeutics N.V. Announces Tender Offer Completion, Intent to Delist, and Board Changes

LVTX

M&A

Delisting/Listing Issues

Board Change

LAVA Therapeutics N.V. announced that 22,877,463 common shares, representing approximately 87% of its outstanding shares, were validly tendered at a purchase price of $1.04 per Share plus one contingent value right (CVR) by the November 12, 2025, expiration of XOMA Royalty Corporation's tender offer, satisfying the minimum condition.
The tendered shares are expected to be accepted for payment on or about November 13, 2025, and a subsequent offering period commenced on the same day, expiring on November 20, 2025.
LAVA has submitted notice to Nasdaq of its intent to voluntarily delist its common shares, with trading expected to be suspended prior to market opening on or about November 21, 2025, and Nasdaq expected to file for removal around November 24, 2025.
As a result of the closing, LAVA Therapeutics N.V. became a majority-owned subsidiary of XOMA Royalty Corporation, and several changes were made to its Board of Directors, with six directors ceasing to serve and four new directors appointed on November 13, 2025.

Nov 13, 2025, 8:40 AM

XOMA Royalty Reports Q3 2025 Financial Results and Business Achievements

LVTX

Earnings

M&A

New Projects/Investments

XOMA Royalty reported net income of $14.1 million for the three months ended September 30, 2025, and $25.6 million for the nine months ended September 30, 2025. Total income and revenues were $9.4 million for the third quarter of 2025 and $38.4 million for the nine months ended September 30, 2025.
As of September 30, 2025, XOMA Royalty had cash and cash equivalents of $130.6 million. The company received $43.9 million in royalties and milestones from partners in the first nine months of 2025, with $14.3 million of that coming from royalties during the third quarter.
XOMA Royalty completed the acquisitions of Turnstone Biologics and HilleVax, and announced the acquisitions of LAVA Therapeutics and Mural Oncology. The acquisition of LAVA Therapeutics is expected to secure royalty economic interests in two early-stage partnered assets.
Key pipeline advancements include Zevra Therapeutics' submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for arimoclomol, and Rezolute Bio's reconfirmed expectation to announce topline data in December from its Phase 3 ersodetug trial.

Nov 12, 2025, 12:30 PM

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award

LVTX

Lisata Therapeutics received the "Overall BioPharma Solution of the Year" award from BioTech Breakthrough for the second consecutive year on November 6, 2025.
The award recognizes Lisata's CendR Platform® technology for its unique therapeutic approach in treating advanced solid tumors.
The company reported positive preliminary results from the ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma, showing a six-month progression-free survival of 60.8% versus 25% for placebo.
The iLSTA trial in locally advanced, non-resectable pancreatic cancer achieved a 60% overall response rate and 100% disease control rate, including one complete response.
Certepetide, Lisata's investigational drug, has demonstrated favorable safety, tolerability, and clinical activity, and has received Fast Track and Orphan Drug designations.

Nov 6, 2025, 1:00 PM

LAVA Therapeutics and XOMA Royalty Amend Purchase Agreement Terms

LVTX

M&A

Takeover Bid

LAVA Therapeutics N.V. and XOMA Royalty Corporation have amended their definitive share purchase agreement, with the cash amount per share for tendering shareholders now set at $1.04, a reduction from the originally agreed range of $1.16 to $1.24.
The amendment introduces a new right for Contingent Value Right (CVR) holders to receive up to approximately $0.23 per CVR, dependent on the final determination of certain potential liabilities.
The minimum net-cash closing condition for the acquisition has been lowered to $24.5 million from the previous $31.5 million.
The tender offer, which was previously scheduled to expire on October 17, 2025, has been extended until November 12, 2025, and the Extraordinary General Meeting of Shareholders is reconvened for November 7, 2025.

Oct 17, 2025, 11:52 AM

Get instant answers from SEC filings, earnings calls & more